Oncobox

Oncobox addresses the critical challenge of selecting the most effective cancer treatments for individual patients. The company posits that a significant number of late-stage cancer patients experience premature mortality due to the absence of data-driven tools that can guide physicians in choosing the optimal drugs tailored to a patient's unique cancer profile. Oncobox offers a cost-effective personalized genetic profiling service designed to empower doctors in making informed treatment decisions. A study involving 900 patients with diverse late-stage cancers, conducted by prominent cancer researchers across Europe and Asia, demonstrated that Oncobox enhanced the efficacy of targeted therapies from 25% to 64%.

The complexity of choosing from over 150 available targeted cancer drugs presents a formidable challenge. Oncobox Dx analyzes tumor DNA, RNA, and molecular pathways, employing sophisticated algorithms to pinpoint the most critical molecular targets in each case. This analysis provides doctors with a clinically actionable report, highlighting the drugs most likely to yield positive outcomes for the patient. The Oncobox team actively seeks partnerships with pharmaceutical companies, hospitals, clinicians, payers, and genomic centers.